中枢神経系（CNS）リンパ腫の世界市場レポート 2025年

中枢神経系（CNS）リンパ腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.6％で19億9,000万米ドルに成長します。予測期間中の成長は、免疫療法の採用拡大、標的治療への注目の高まり、中枢神経系リンパ腫の有病率の上昇、ヘルスケアへの患者アクセスの改善、政府の支援やイニシアチブなどの要因によるものと考えられます。この期間の主な動向としては、診断における人工知能の統合、次世代モノクローナル抗体の開発、低侵襲治療へのシフト、精密医療の進展、診断技術の革新などが挙げられます。

心理障害の発生率の増加は、中枢神経系（CNS）リンパ腫市場の成長を大きく牽引すると予想されます。思考、感情、行動に影響を及ぼす心理障害は、ストレス、社会的孤立、経済的圧力、遺伝、薬物乱用、デジタル技術の過剰使用などの要因によって影響を受ける。これらの疾患の有病率が上昇するにつれ、脳の炎症、免疫系の相互作用、血液脳関門の理解を深める神経腫瘍学研究が進展します。このような深い洞察は、がんと精神疾患の両方に対するより良い治療法の開発に貢献します。例えば、全米精神疾患同盟（National Alliance on Mental Illness）は2024年、米国では毎年60万件近くの入院が18～44歳の精神病スペクトラムと気分障害によるものであると報告しています。したがって、精神疾患の発生率の上昇は、中枢神経系リンパ腫市場の成長を促進する役割を果たしています。

神経疾患の有病率の増加は、中枢神経系（CNS）リンパ腫市場を押し上げるもう1つの要因です。脳、脊髄、神経に影響を及ぼす神経疾患は、遺伝、感染、外傷、毒素、自己免疫反応、変性過程などの要因により、より一般的になりつつあります。中枢神経系リンパ腫の研究は、脳機能、免疫反応、神経炎症の理解を深めることで、神経疾患の診断や治療の進歩に大きく貢献しています。例えば、2022年4月、欧州脳会議（European Brain Council）は、600以上の神経疾患と300近くの精神疾患が、てんかん患者6,500万人を含む世界中の数百万人に影響を及ぼしていると報告しました。さらに、欧州では認知症の患者数が2022年の1,050万人から2050年には1,870万人に増加するという予測もあります。このように、神経疾患の有病率の増加は需要を刺激し、中枢神経系リンパ腫市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界中枢神経系（CNS）リンパ腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の中枢神経系（CNS）リンパ腫市場：成長率分析
• 世界の中枢神経系（CNS）リンパ腫市場の実績：規模と成長, 2019-2024
• 世界の中枢神経系（CNS）リンパ腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界中枢神経系（CNS）リンパ腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の中枢神経系（CNS）リンパ腫市場薬物の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 化学療法剤
• コルチコステロイド
• 世界の中枢神経系（CNS）リンパ腫市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 放射線治療
• ステロイド療法
• 標的療法
• 世界の中枢神経系（CNS）リンパ腫市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 外来手術サービス
• その他の用途
• 世界の中枢神経系（CNS）リンパ腫市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗CD20モノクローナル抗体
• 抗PD-1モノクローナル抗体
• その他の標的モノクローナル抗体
• 世界の中枢神経系（CNS）リンパ腫市場化学療法剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 代謝拮抗剤
• トポイソメラーゼ阻害剤
• 世界の中枢神経系（CNS）リンパ腫市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デキサメタゾン
• プレドニゾロン
• メチルプレドニゾロン

第7章 地域別・国別分析

• 世界の中枢神経系（CNS）リンパ腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の中枢神経系（CNS）リンパ腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 中枢神経系（CNS）リンパ腫市場：競合情勢
• 中枢神経系（CNS）リンパ腫市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Fresenius SE & Co. KGaA
• Incyte Corporation
• ONO PHARMA USA Inc.
• Kazia Therapeutics Limited
• Simcere Pharmaceutical Group Limited
• Karyopharm Therapeutics Inc.
• Nurix Therapeutics Inc.
• CNS Pharmaceuticals Inc.
• JW Therapeutics
• PentixaPharm Pty Ltd
• Cellectar Biosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 中枢神経系（CNS）リンパ腫市場2029：新たな機会を提供する国
• 中枢神経系（CNS）リンパ腫市場2029：新たな機会を提供するセグメント
• 中枢神経系（CNS）リンパ腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Central nervous system (CNS) lymphoma is a rare and aggressive form of lymphoma that originates in the brain or spinal cord. The primary goal of treatment is to target and shrink cancerous cells in the CNS, alleviate symptoms, and improve survival rates through a combination of medications, targeted therapies, and focused high-energy treatments.

The main drugs in the central nervous system (CNS) lymphoma market include monoclonal antibodies, chemotherapeutic agents, and corticosteroids. Monoclonal antibodies are laboratory-created proteins that replicate the immune system's ability to identify and neutralize specific targets, such as cancer cells, viruses, or inflammatory molecules. These treatments are administered through various methods, including chemotherapy, radiation therapy, steroid therapy, and targeted therapy. The market also serves a range of applications, including hospitals, clinics, ambulatory surgical services, and other healthcare settings.

The central nervous system (CNS) lymphoma market research report is one of a series of new reports from The Business Research Company that provides central nervous system (CNS) lymphoma market statistics, including the central nervous system (CNS) lymphoma industry global market size, regional shares, competitors with the central nervous system (CNS) lymphoma market share, detailed central nervous system (CNS) lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the central nervous system (CNS) lymphoma industry. This central nervous system (CNS) lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system (CNS) lymphoma market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historical period can be attributed to factors such as increased awareness and diagnosis, a rising incidence of lymphoma, a growing number of clinical trials, increased funding for cancer research, and a greater use of biomarkers for targeted treatments.

The central nervous system (CNS) lymphoma market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to factors such as the growing adoption of immunotherapy, an increasing focus on targeted treatments, a rising prevalence of CNS lymphoma, improved patient access to healthcare, and government support and initiatives. Key trends during this period include the integration of artificial intelligence in diagnostics, the development of next-generation monoclonal antibodies, a shift toward less invasive treatments, advancements in precision medicine, and innovations in diagnostic technologies.

The increasing incidence of psychological disorders is expected to significantly drive the growth of the central nervous system (CNS) lymphoma market. Psychological disorders, which affect thoughts, emotions, and behaviors, are influenced by factors such as stress, social isolation, economic pressures, genetics, substance abuse, and excessive use of digital technologies. As the prevalence of these disorders rises, it advances neuro-oncology research, which enhances the understanding of brain inflammation, immune system interactions, and the blood-brain barrier. This deeper insight contributes to the development of better treatments for both cancer and mental health conditions. For instance, the National Alliance on Mental Illness reported in 2024 that nearly 600,000 hospitalizations in the U.S. each year are due to psychosis spectrum and mood disorders among individuals aged 18-44. Therefore, the rising incidence of psychological disorders plays a role in propelling growth in the CNS lymphoma market.

The increasing prevalence of neurological disorders is another factor expected to boost the central nervous system (CNS) lymphoma market. Neurological disorders, which affect the brain, spinal cord, and nerves, are becoming more common due to factors such as genetics, infections, trauma, toxins, autoimmune responses, and degenerative processes. CNS lymphoma research contributes significantly to advancing diagnostics and treatments for neurological disorders by improving understanding of brain function, immune response, and neuroinflammation. For example, in April 2022, the European Brain Council reported that over 600 neurological diseases and nearly 300 psychiatric conditions impact millions of people worldwide, including 65 million with epilepsy. Additionally, projections indicate that the number of people in Europe affected by dementia will rise from 10.5 million in 2022 to 18.7 million by 2050. As such, the growing prevalence of neurological disorders is expected to fuel demand and drive the growth of the CNS lymphoma market.

In March 2023, ONO Pharma Inc. received orphan drug designation from the U.S. Food and Drug Administration (FDA) for tirabrutinib (ONO-4059) as a treatment for PCNSL. Currently under investigation in the phase 2 PROSPECT study, tirabrutinib targets critical pathways involved in B-cell proliferation and survival, offering new potential treatment options for B-cell malignancies such as primary CNS lymphoma. This highlights the ongoing efforts to develop innovative therapies to address CNS lymphoma and related neurological conditions.

Major players in the central nervous system (CNS) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Incyte Corporation, ONO PHARMA USA Inc., Kazia Therapeutics Limited, Simcere Pharmaceutical Group Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc.

North America was the largest region in the central nervous system (CNS) lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system (CNS) lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the central nervous system (CNS) lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The central nervous system (CNS) lymphoma market consists of revenues earned by entities by providing services such as diagnostic service, therapy services, and supportive and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system (CNS) lymphoma market also includes sales of drugs, therapy equipment, supportive therapies, and surgical instruments & tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System (CNS) Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system (cns) lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system (cns) lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system (cns) lymphoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Class Of Drugs: Monoclonal antibodies; Chemotherapeutic Agents; Corticosteroids
• 2) By Treatment: Chemotherapy; Radiation Therapy; Steroid Therapy; Targeted Therapy
• 3) By Application: Hospitals; Clinics; Ambulatory Surgical Services; Other Applications
• Subsegments:
• 1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies; Anti-PD-1 Monoclonal Antibodies; Other Targeted Monoclonal Antibodies
• 2) By Chemotherapeutic Agents: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors
• 3) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Central Nervous System (CNS) Lymphoma Market Characteristics

3. Central Nervous System (CNS) Lymphoma Market Trends And Strategies

4. Central Nervous System (CNS) Lymphoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Central Nervous System (CNS) Lymphoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Central Nervous System (CNS) Lymphoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Central Nervous System (CNS) Lymphoma Market Growth Rate Analysis
• 5.4. Global Central Nervous System (CNS) Lymphoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Central Nervous System (CNS) Lymphoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Central Nervous System (CNS) Lymphoma Total Addressable Market (TAM)

6. Central Nervous System (CNS) Lymphoma Market Segmentation

• 6.1. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal antibodies
• Chemotherapeutic Agents
• Corticosteroids
• 6.2. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Radiation Therapy
• Steroid Therapy
• Targeted Therapy
• 6.3. Global Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Surgical Services
• Other Applications
• 6.4. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-CD20 Monoclonal Antibodies
• Anti-PD-1 Monoclonal Antibodies
• Other Targeted Monoclonal Antibodies
• 6.5. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Chemotherapeutic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• Topoisomerase Inhibitors
• 6.6. Global Central Nervous System (CNS) Lymphoma Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Prednisolone
• Methylprednisolone

7. Central Nervous System (CNS) Lymphoma Market Regional And Country Analysis

• 7.1. Global Central Nervous System (CNS) Lymphoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Central Nervous System (CNS) Lymphoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Central Nervous System (CNS) Lymphoma Market

• 8.1. Asia-Pacific Central Nervous System (CNS) Lymphoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Central Nervous System (CNS) Lymphoma Market

• 9.1. China Central Nervous System (CNS) Lymphoma Market Overview
• 9.2. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Central Nervous System (CNS) Lymphoma Market

• 10.1. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Central Nervous System (CNS) Lymphoma Market

• 11.1. Japan Central Nervous System (CNS) Lymphoma Market Overview
• 11.2. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Central Nervous System (CNS) Lymphoma Market

• 12.1. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Central Nervous System (CNS) Lymphoma Market

• 13.1. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Central Nervous System (CNS) Lymphoma Market

• 14.1. South Korea Central Nervous System (CNS) Lymphoma Market Overview
• 14.2. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Central Nervous System (CNS) Lymphoma Market

• 15.1. Western Europe Central Nervous System (CNS) Lymphoma Market Overview
• 15.2. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Central Nervous System (CNS) Lymphoma Market

• 16.1. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Central Nervous System (CNS) Lymphoma Market

• 17.1. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Central Nervous System (CNS) Lymphoma Market

• 18.1. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Central Nervous System (CNS) Lymphoma Market

• 19.1. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Central Nervous System (CNS) Lymphoma Market

• 20.1. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Central Nervous System (CNS) Lymphoma Market

• 21.1. Eastern Europe Central Nervous System (CNS) Lymphoma Market Overview
• 21.2. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Central Nervous System (CNS) Lymphoma Market

• 22.1. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Central Nervous System (CNS) Lymphoma Market

• 23.1. North America Central Nervous System (CNS) Lymphoma Market Overview
• 23.2. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Central Nervous System (CNS) Lymphoma Market

• 24.1. USA Central Nervous System (CNS) Lymphoma Market Overview
• 24.2. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Central Nervous System (CNS) Lymphoma Market

• 25.1. Canada Central Nervous System (CNS) Lymphoma Market Overview
• 25.2. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Central Nervous System (CNS) Lymphoma Market

• 26.1. South America Central Nervous System (CNS) Lymphoma Market Overview
• 26.2. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Central Nervous System (CNS) Lymphoma Market

• 27.1. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Central Nervous System (CNS) Lymphoma Market

• 28.1. Middle East Central Nervous System (CNS) Lymphoma Market Overview
• 28.2. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Central Nervous System (CNS) Lymphoma Market

• 29.1. Africa Central Nervous System (CNS) Lymphoma Market Overview
• 29.2. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Class Of Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Central Nervous System (CNS) Lymphoma Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Central Nervous System (CNS) Lymphoma Market Competitive Landscape And Company Profiles

• 30.1. Central Nervous System (CNS) Lymphoma Market Competitive Landscape
• 30.2. Central Nervous System (CNS) Lymphoma Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Central Nervous System (CNS) Lymphoma Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Fresenius SE & Co. KGaA
• 31.6. Incyte Corporation
• 31.7. ONO PHARMA USA Inc.
• 31.8. Kazia Therapeutics Limited
• 31.9. Simcere Pharmaceutical Group Limited
• 31.10. Karyopharm Therapeutics Inc.
• 31.11. Nurix Therapeutics Inc.
• 31.12. CNS Pharmaceuticals Inc.
• 31.13. JW Therapeutics
• 31.14. PentixaPharm Pty Ltd
• 31.15. Cellectar Biosciences Inc.

32. Global Central Nervous System (CNS) Lymphoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System (CNS) Lymphoma Market

34. Recent Developments In The Central Nervous System (CNS) Lymphoma Market

35. Central Nervous System (CNS) Lymphoma Market High Potential Countries, Segments and Strategies

• 35.1 Central Nervous System (CNS) Lymphoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Central Nervous System (CNS) Lymphoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Central Nervous System (CNS) Lymphoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer